Skip to main content
. 2018 Feb 6;13(2):e0191953. doi: 10.1371/journal.pone.0191953

Fig 1.

Fig 1

a) Cost-effectiveness plane and b) cost-effectiveness acceptability curve for liraglutide 1.8 mg versus lixisenatide (each added to basal insulin). Probabilistic sensitivity analysis conducted with 1000 simulations. Base-case with 3% discount rate. QALY, quality-adjusted life-year; SEK, Swedish kronor.